PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22086611-8	2013	In contrast, lapatinib produced an accumulation of cells in the G(1) phase mediated through cyclin D1, but only in lapatinib-sensitive cells.	Lapatinib	13-22	cyclin D1	Homo sapiens	92-101	
27633099-5	2016	Furthermore, the phosphorylation levels of ErbB2, ErbB3 and Akt and the protein levels of cyclin D1 were decreased by lapatinib treatment of HSC3, HSC4 and Ca9-22 cells.	Lapatinib	118-127	cyclin D1	Homo sapiens	90-99	
26124325-11	2015	We demonstrated a statistically significant lapatinib- and gefitinib-induced repression of cyclin D1, MMP9 and beta-catenin in CERV196 cells dependent on incubation time.	Lapatinib	44-53	cyclin D1	Homo sapiens	91-100	
26124325-12	2015	CONCLUSION: Cyclin D1 and MMP9 expression profiles may represent an early measure of sensitivity and level of response to lapatinib and gefitinib.	Lapatinib	122-131	cyclin D1	Homo sapiens	12-21	
22709873-11	2012	Additionally, Cyclin D1 (CCND1), a common regulator of the other four proteins, was also demonstrated to observe a proportional response to lapatinib exposure.	Lapatinib	140-149	cyclin D1	Homo sapiens	14-23	
22709873-11	2012	Additionally, Cyclin D1 (CCND1), a common regulator of the other four proteins, was also demonstrated to observe a proportional response to lapatinib exposure.	Lapatinib	140-149	cyclin D1	Homo sapiens	25-30	
21989330-0	2012	The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.	Lapatinib	70-79	cyclin D1	Homo sapiens	4-13	
21989330-0	2012	The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.	Lapatinib	70-79	cyclin D1	Homo sapiens	15-20	
20571878-8	2011	For the most lapatinib-sensitive cell line (HK1-LMP1, with IC(50) ~ 600 nM), which harbored the highest levels of both EGFR and HER-2, inhibition of cell growth was associated G(0)/G(1) cell cycle arrest, marked PARP cleavage, caspase-3 cleavage, as well as significant downregulation of several important survival proteins (e.g. survivin, Mcl-1 and cyclin D1).	Lapatinib	13-22	cyclin D1	Homo sapiens	350-359	
19141783-7	2009	Lapatinib also effectively blocked epidermal growth factor-induced signaling through the EGFR and ErbB2 receptors, suppressed cyclin D1 and epiregulin mRNA expression, and stimulated p27 mRNA expression in human mammary epithelial cells and in mammary epithelial cells from mice treated for 5 months with high-dose lapatinib.	Lapatinib	0-9	cyclin D1	Homo sapiens	126-135	
19141783-8	2009	Thus, cyclin D1, epiregulin, and p27 may represent useful biomarkers of lapatinib response in patients.	Lapatinib	72-81	cyclin D1	Homo sapiens	6-15	
17513611-7	2007	After 12 h of exposure to 1.0 micromol/L of lapatinib, AKT1, MAPK9, HSPCA, IRAK1, and CCND1 transcripts were down-regulated 7- to 25-fold in responsive BT474 and SKBr3 cells.	Lapatinib	44-53	cyclin D1	Homo sapiens	86-91